This is not unusual in Lyme disease. It is structurally expected.
Standard two-tier serology (ELISA + Western blot) has documented sensitivity as low as 29–40% in early localized disease. [2] The CDC acknowledges serologic assays can remain falsely negative for 4–6 weeks post-infection — and that antibody titers, once elevated, cannot be used to determine cure. [1] A positive result does not confirm active infection. A negative result does not rule it out.
The problem runs deeper than timing windows. Borrelia burgdorferi actively modulates its own antigenicity — downregulating surface proteins like OspC as host antibody pressure mounts, and undergoing continuous recombination at the VlsE locus to vary the very epitopes serological tests are designed to detect. [3] The immune system is responding. The pathogen is changing the question.
Cross-reactivity compounds this further. In a large US military cohort of 15,928 individuals, 53.3% of positive IgM immunoblots were determined to be false positives — and antibiotics were prescribed in 80.5% of those false-positive cases. [4] The test is not just missing the disease. It is actively misdirecting clinical decisions in both directions.
"A test that measures the immune response to a pathogen that systematically disrupts immune responses is, structurally, an unreliable witness."
The autonomic nervous system has no antibody response to manipulate. It doesn't seroconvert. It doesn't cross-react with EBV, syphilis, or rheumatoid factor. It responds to physiological load — continuously, measurably, and with a temporal resolution that a blood draw taken weeks apart cannot approximate.
Continuous nocturnal HRV monitoring captures what serology cannot: the real-time functional state of the organism under pathogen load. Where a blood test gives you a binary signal at a single point in time, longitudinal RMSSD tracking gives you a film of the autonomic system's response across weeks.
This is not a new hypothesis. Reduced RMSSD in ME/CFS versus healthy controls has been confirmed in meta-analysis (SMD −0.37, p=.02, 64 studies). [6] Wearable HRV has been shown to remain abnormal for 24 hours post-exertion in Long COVID patients — corroborating its use as a continuous functional biomarker in post-acute infectious conditions. [5]
"For a pathogen whose primary survival strategy is immune evasion, a biomarker that bypasses the immune response entirely is not a luxury — it is a logical necessity."
From my own longitudinal dataset — 200 consecutive days combining nocturnal HRV monitoring (Polar Grit X2 + Kubios HRV) with a 5-domain symptom diary (DIARY_v2: global severity, fatigue, cognitive fog, post-exertional malaise, autonomic dysfunction) — the pattern is consistent with what the literature describes, and extends it in one specific direction.
ANS suppression was present on a significant proportion of recorded days, with nocturnal RMSSD values clustering in ranges consistent with post-infectious autonomic dysregulation — in periods of negative or borderline serology. The blood was silent. The nervous system was not.
Five independent models now predict distinct symptom dimensions 24–48 hours ahead. Severity prediction achieves an AUC of 0.84 (LOO-CV, Bootstrap 1000×, n=60 training pairs). Autonomic dysfunction prediction reaches AUC 0.86 — using advanced HRV features like LF/HF ratio and SD1 from raw RR intervals. The signal is not only present — it is physiologically coherent. Sleep score showed no predictive value (ρ≈0). The signal is in the autonomic system, not in subjective rest quality.
This is not a claim that HRV replaces diagnosis. It is a claim that for a disease that hides this well, continuous monitoring provides the temporal correlation that serology — by its own structural limitations — cannot.